Actinium Pharmaceuticals, Inc. (ATNM): Sloan-kettering Cance Memorial , 10% owner of Actinium Pharmaceuticals, Inc. sold 17,790 shares on Jun 2, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $2.01 per share for a total value of $35,715.80 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, Sloan-kettering Cance Memorial (10% owner) sold 169,450 shares at $1.98 per share price.On Apr 18, 2016, C. David Nicholson, (director) purchased 5,000 shares at $2.00 per share price.Also, On Apr 18, 2016, Sergio Traversa (director) purchased 3,000 shares at $2.02 per share price.On Apr 18, 2016, Sandesh Seth (director other) purchased 15,000 shares at $2.00 per share price.
Shares of Actinium Pharmaceuticals Inc (ATNM) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -4.74% at $1.81 with 3,31,310 shares getting traded. Post opening the session at $1.9, the shares hit an intraday low of $1.79 and an intraday high of $1.9499 and the price vacillated in this range throughout the day. The company has a market cap of $85 M and the number of outstanding shares has been calculated to be 4,69,50,180 shares. The 52-week high of Actinium Pharmaceuticals Inc is $3.5 and the 52-week low is $1.52.
Actinium Pharmaceuticals Inc. (Actinium) is a biopharmaceutical company engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company’s products include Actimab-A an antibody-drug construct containing actinium 225 (Ac-225) and Iomab-B an antibody-drug construct containing iodine 131 (I-131). As of December 31 2014 Actinium’s Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. As of December 31 2014 the Company had four product candidates in clinical trials: Actimab-A (HuM195-Ac-225) Iomab-B (BC8-I-131) BC8-Y-90 and BC8-SA. As of December 31 2014 BC8-Y-90 and BC8-SA were in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).